加载中
NASDAQHealthcareBiotechnology
最新数据
US$1.12
−US$0.03 · -2.61%
Telomir Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical firm, concentrating its efforts on creating and launching novel therapeutic interventions. Its primary focus involves the development of TELOMIR-1, an innovative small molecule compound. This oral medication is being engineered to serve as a therapeutic solution against various age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, and also to assist in recovery post-chemotherapy. It achieves this by disrupting and inhibiting inflammatory pathways that are triggered by interleukin-17. Established in 2021, the company was initially known as Metallo Therapies Inc., officially adopting the name Telomir Pharmaceuticals, Inc. on October 10, 2022. The company's headquarters are located in Baltimore, Maryland.
前收盘价
US$1.12
−US$0.03 · -2.61%
盘前
US$1.12
US$0.00 · 0.00%
10月12日 5:27 ET
盘中时间采用ET。市场数据可能有所延迟。
Telomir Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical firm, concentrating its efforts on creating and launching novel therapeutic interventions. Its primary focus involves the development of TELOMIR-1, an innovative small molecule compound. This oral medication is being engineered to serve as a therapeutic solution against various age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, and also to assist in recovery post-chemotherapy. It achieves this by disrupting and inhibiting inflammatory pathways that are triggered by interleukin-17. Established in 2021, the company was initially known as Metallo Therapies Inc., officially adopting the name Telomir Pharmaceuticals, Inc. on October 10, 2022. The company's headquarters are located in Baltimore, Maryland.
日内区间
当前US$1.12
52周区间
当前US$1.12
盘中时间采用ET。市场数据可能有所延迟。
Telomir Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical firm, concentrating its efforts on creating and launching novel therapeutic interventions. Its primary focus involves the development of TELOMIR-1, an innovative small molecule compound. This oral medication is being engineered to serve as a therapeutic solution against various age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, and also to assist in recovery post-chemotherapy. It achieves this by disrupting and inhibiting inflammatory pathways that are triggered by interleukin-17. Established in 2021, the company was initially known as Metallo Therapies Inc., officially adopting the name Telomir Pharmaceuticals, Inc. on October 10, 2022. The company's headquarters are located in Baltimore, Maryland.
日内区间
当前US$1.12
52周区间
当前US$1.12
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 243.56万 USD | 223.53万 USD | 157.43万 USD | 83.32万 USD | 12.65万 USD |
| 销售、一般及管理费用 | 810.33万 USD | 963.63万 USD | 60.02万 USD | 2.09万 USD | 1.16万 USD |
| 营业费用 | 1053.88万 USD | 1224.22万 USD | 394.2万 USD | 85.41万 USD | 13.81万 USD |
| 利息收入 | 12.56万 USD | 4.8万 USD | — | — | — |
| 利息支出 | — | −433.85万 USD | 164.3万 USD | — | — |
| 折旧和摊销 | — | 433.85万 USD | — | 85.41万 USD | 13.81万 USD |
| 营业利润 | −1053.88万 USD | −1224.22万 USD | −394.2万 USD | −85.41万 USD | −13.81万 USD |
| 净利润 | −1041.32万 USD | −1653.27万 USD | −1307.19万 USD | −85.41万 USD | −13.81万 USD |
公司数据更新于 2026年10月12日。
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
